Older adults with functional impairments may be at a higher risk of medical cannabis use, as well as prescription opioid and tranquilizer or sedative misuse, suggests new research published in the online edition of the American Journal of Preventive Medicine.

New research published in JAMA Network shows that nationwide naloxone prescriptions declined at the start of the pandemic and have yet to reach pre-pandemic levels.

On April 30, FDA announced the approval of a higher dosage of naloxone hydrochloride nasal spray (Kloxxado—Hikma Pharmaceuticals) to treat opioid overdose. The newly approved product delivers 8 mg of naloxone into the nasal cavity, compared with previously approved 2- and 4-mg naloxone nasal spray products.

More than 87,000 Americans died from drug overdoses in the 12-month period that ended in September 2020, according to preliminary CDC data, which indicate that the U.S. drug overdose mortality rate increased last year.